Dendritic Cells: Biology and Clinical Applications

Dendritic Cells - Biology and Clinical Applications (Hardcover)

---

Please choose whether or not you want other users to be able to see on your profile that this library is a favorite of yours.

Finding libraries that hold this item You may have already requested this item. Please select Ok if you would like to proceed with this request anyway. WorldCat is the world's largest library catalog, helping you find library materials online.

Clinical Applications of Dendritic Cell Cancer Vaccines

Don't have an account? Your Web browser is not enabled for JavaScript. Some features of WorldCat will not be available. Create lists, bibliographies and reviews: Search WorldCat Find items in libraries near you. Advanced Search Find a Library. Your list has reached the maximum number of items.

Please create a new list with a new name; move some items to a new or existing list; or delete some items. Your request to send this item has been completed.

Dendritic Cells and Cellular Immunity to Tumors

Citations are based on reference standards. However, formatting rules can vary widely between applications and fields of interest or study. The specific requirements or preferences of your reviewing publisher, classroom teacher, institution or organization should be applied.

Clinical Applications of Dendritic Cell Cancer Vaccines

The E-mail Address es field is required. Please enter recipient e-mail address es. The E-mail Address es you entered is are not in a valid format. Please re-enter recipient e-mail address es. You may send this item to up to five recipients.

The name field is required. Please enter your name. The E-mail message field is required.

Please enter the message. Please verify that you are not a robot. Would you also like to submit a review for this item? You already recently rated this item. Your rating has been recorded. Write a review Rate this item: Preview this item Preview this item.

English View all editions and formats Summary:. Allow this favorite library to be seen by others Keep this favorite library private.

Find a copy in the library

Find a copy in the library Finding libraries that hold this item User-contributed reviews Add a review and share your thoughts with other readers. Patients received a series of three or four infusions of antigen-pulsed DCs followed by s. Antitumor cellular immune responses were detected in all four patients, and three of the four patients had either partial or total regression of detectable disease. Keyhole limpet hemocyanin was added as a CD4 helper antigen and immunological tracer molecule. DC vaccination induced a positive peptide-specific delayed-type hypersensitivity DTH response in 11 patients.

Five of 16 patients demonstrated objective responses to the DC vaccine two complete responses, three partial responses with regression of metastases in various organs skin, soft tissue, lung, and pancreas. In a report from Chakraborty et al.

3 editions of this work

One patient had a partial regression of an s. Nine patients had a DTH response at the vaccine site. In a report by Mukherji et al. Vaccination induced autologous melanoma-reactive and peptide-specific CTL responses. In particular, the frequency of circulating autologous melanoma-reactive CTL precursors was increased. In a follow-up study, Hu et al. The authors performed a phase 1 clinical trial assessing the administration of autologous DCs pulsed with an HLA-Aspecific prostate-specific membrane antigen PSMA for the treatment of 51 men with hormone-refractory prostate cancer.

An average decrease in PSA was observed only in group 5. Seven men had partial responses. DCs were pulsed with autologous Id protein and administered to a patient with advanced-stage refractory MM. Id-specific immune responses were detected, as characterized by T-cell-proliferative responses and the production of anti-Id antibodies. A T-cell line generated after vaccination lysed autologous Id-pulsed targets and recognized fresh autologous MM cells. All of these studies have demonstrated that the administration of the various DC vaccines is safe with little or no toxicity.

DC-based cancer vaccines offer the potential for an effective, non-toxic, and outpatient-based approach to cancer therapy. As depicted in Figure 1 , future-generation clinical trials will undoubtedly incorporate DCs pulsed with tumor epitopes derived from newly identified tumor-associated peptides, RNA, lysates, or apoptotic bodies. While the majority of DC-based clinical trials is being undertaken in patients with melanoma, such trials will eventually serve as a basis for future DC vaccine trials incorporating patients with more common malignancies such as breast, colon, lung, and prostate cancer.

As a result of the major advances in cancer immunobiology, we now find ourselves at the threshold of a novel, exciting, and hopefully rewarding approach to the treatment of cancer. Coley would be amazed and gratified by the progress achieved in the immunotherapy of cancer. Future directions for dendritic cell-based vaccines for cancer. User Name Password Sign In.

Previous Section Next Section.

Account Options

In this window In a new window. The treatment of inoperable sarcoma by bacterial toxins the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigius. Peptide-priming of cytolytic T cell immunity in vivo using microglobulin as an adjuvant. J Immunol ; Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature ; CrossRef Medline Google Scholar.

Allele specific motifs revealed by sequencing of self peptides eluted from MHC molecules. J Exp Med ; Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today ; Blood ; Proliferating dendritic cell progenitors in human blood. Identification of proliferating dendritic cell precursor in mouse blood. J Exp Med b ; Exp Hematol ; Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: Influence of dendritic cells on tumor growth.

Young JW, Inaba K.

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells. Cancer Immunol Immunother ; Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat Med ; 1: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.

Eur J Immunol ; Therapy of murine tumors with tumor peptide-pulsed dendritic cells: IL engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann New York Acad Sci ; T cell recognition of transforming protein encoded by mutated ras proto-oncogenes. Immunity ; 2:

• The Princess and the Weaver
• Gold Panning Instructions
• Chapter 37, Getting from 1,000 Genes to a Triad of Symptoms: The Emerging Role of Systems Biology in Autism Spectrum Disorders
• Psychopharmacology of the Developmental Disabilities (Disorders of Human Learning, Behavior, and Communication)
• Politics of Origin in Africa: Autochthony, Citizenship and Conflict